NASDAQ:NEPH - Nephros Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.83
  • Forecasted Upside: 84.44 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.50
▼ -0.01 (-0.13%)

This chart shows the closing price for NEPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nephros Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NEPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NEPH

Analyst Price Target is $13.83
▲ +84.44% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Nephros in the last 3 months. The average price target is $13.83, with a high forecast of $16.00 and a low forecast of $12.50. The average price target represents a 84.44% upside from the last price of $7.50.

This chart shows the closing price for NEPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Nephros. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/8/2021Maxim GroupReiterated RatingBuy$16.00Medium
8/11/2021B. RileyReiterated RatingBuy$12.50Low
6/29/2021BenchmarkReiterated RatingBuy$13.00High
5/7/2021Maxim GroupReiterated RatingBuy$16.00High
1/26/2021B. RileyInitiated CoverageBuy$12.50High
4/3/2020Maxim GroupReiterated RatingBuy$16.00Low
2/29/2020Maxim GroupReiterated RatingBuy$16.00High
1/7/2020Maxim GroupReiterated RatingBuy$16.00Medium
11/7/2019Maxim GroupReiterated RatingBuy$16.00High
10/24/2019BenchmarkInitiated CoverageBuy$16.00Low
10/4/2019Maxim GroupInitiated CoverageBuy$16.00High
4/24/2019Taglich BrothersReiterated RatingSpeculative BuyHigh
(Data available from 10/22/2016 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/24/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/23/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/22/2021

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Nephros logo
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Renal Products segment comprises of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.
Read More

Today's Range

Now: $7.50
Low: $7.36
High: $7.53

50 Day Range

MA: $8.34
Low: $7.60
High: $9.10

52 Week Range

Now: $7.50
Low: $5.69
High: $11.67

Volume

3,215 shs

Average Volume

11,932 shs

Market Capitalization

$76.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Nephros?

The following sell-side analysts have issued research reports on Nephros in the last twelve months: B. Riley, Benchmark Co., Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for NEPH.

What is the current price target for Nephros?

3 Wall Street analysts have set twelve-month price targets for Nephros in the last year. Their average twelve-month price target is $13.83, suggesting a possible upside of 84.4%. Maxim Group has the highest price target set, predicting NEPH will reach $16.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $12.50 for Nephros in the next year.
View the latest price targets for NEPH.

What is the current consensus analyst rating for Nephros?

Nephros currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NEPH will outperform the market and that investors should add to their positions of Nephros.
View the latest ratings for NEPH.

What other companies compete with Nephros?

How do I contact Nephros' investor relations team?

Nephros' physical mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company's listed phone number is (201) 343-5202 and its investor relations email address is [email protected] The official website for Nephros is www.nephros.com.